시장보고서

상품코드

2076114

유전성 만성 폐쇄성 폐질환(COPD) 시장 : 약제 클래스별, 투여 경로별, 유통 채널별 및 지역별

Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Drug Class, By Route of Administration, By Distribution Channel, and By Region

발행일: 2026년 04월 | 리서치사: 구분자

Coherent Market Insights | 페이지 정보: 영문 | 배송안내 : 2-3일 (영업일 기준)

가격

Unprintable PDF & Excel (Single User License)

PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며, 텍스트의 Copy&Paste도 불가능합니다.

US $ 4,500

￦ 6,704,000

PDF & Excel (Multi User License - Up to 7 Users)

PDF & Excel 보고서를 동일 기업 최대 7명까지 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능하며, 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

US $ 7,000

￦ 10,428,000

PDF & Excel (Corporate User License)

PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,000

￦ 14,898,000

※ 부가세 별도

한글목차

영문목차

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

유전성 만성 폐쇄성 폐질환(COPD) 시장은 2026년에 6억 3,640만 달러 규모에 이를 것으로 추정되고 있어 2033년까지 8억 430만 달러에 이를 것으로 예상되고 있습니다. 2026년부터 2033년까지 CAGR 3.4%로 성장할 전망입니다.

보고서 범위		보고서 상세
기준 연도 :	2025년	2026년 시장 규모 :	6억 3,640만 달러
과거 데이터 기간 :	2020-2024년	예측 기간 :	2026-2033년
2026-2033년 예측 기간 CAGR :	3.40%	2033년 시장 규모 예측 :	8억 430만 달러

α-1 결핍증과 관련된 폐기종은 유전성 만성 폐쇄성 폐질환(COPD)이라고 불리며, 폐의 염증을 동반하고 폐에서 나오는 기류의 폐쇄를 유발합니다. 이는 만성 질환으로, 증상으로는 천명음, 가래 분비, 호흡 곤란 등이 있습니다. 만성 기관지염, 폐기종, 난치성 천식은 모두 퇴행성 폐질환인 COPD의 증상입니다. 만성 폐쇄성 폐질환(COPD)은 주로 흡연, 대기 오염, 간접흡연, α-1 결핍증 관련 폐기종(COPD의 드문 형태) 및 기타 요인에 의해 유발됩니다.

매년 수백만 명의 사람들이 만성 폐쇄성 폐질환, 줄여서 COPD에 걸리고 있습니다. 폐기종과 만성 기관지염은 통칭하여 COPD라고 불리는 두 가지 질환입니다. 폐기종에서는 폐의 기포(공기 주머니)가 손상됩니다. 운동 시 숨이 차는 것은 폐기종의 초기 징후입니다. 그 후, 안정 상태에서도 호흡 곤란이 나타나게 됩니다. 만성 폐쇄성 폐질환(COPD)에는 경증부터 매우 중증에 이르기까지 4단계가 있습니다. 증상으로는 지속적인 기침, 호흡 곤란, 천명음 등이 있습니다.

시장 역학

시장의 주요 기업들이 제품 출시나 승인 획득과 같은 유기적 전략을 더욱 적극적으로 채택함에 따라, 예측 기간 동안 시장 성장이 견인될 것으로 예측됩니다. 예를 들어, 2020년 9월, 제약회사인 GSK Plc.와 헬스케어 전문 자산운용사인 Innoviva Inc.는 미국 식품의약국(FDA)이 트레레지 엘립타(플루티카손 플루오레이트/우메클리디늄/빌란테롤 “FF/UMEC/VI”)에 대해, 18세 이상 환자를 대상으로 한 천식 치료의 새로운 적응증을 승인하고, 만성 폐쇄성 폐질환(COPD) 환자에 대한 사용과 관련된 현행 승인 범위를 확대했다고 발표했습니다. 트레레지 엘립타는 급성 기관지 경련의 완화에는 적응증이 아닙니다. 또한, 주로 COPD를 대상으로 하는 여러 개발 중인 약물이 호흡기 질환 분야의 파이프라인에 포함되어 있으며, 이들이 전 세계 만성 폐쇄성 폐질환(COPD) 시장의 성장을 견인할 것으로 예측됩니다.

본 조사의 주요 특징:

본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 유전성 만성 폐쇄성 폐질환(COPD) 치료 시장의 주요 기업 프로파일을 분석했습니다.
본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
이 세계 유전성 만성 폐쇄성 폐질환(COPD) 치료 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
이해관계자들은 전 세계 유전성 만성 폐쇄성 폐질환(COPD) 치료 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.

Report Coverage	Report Details
Base Year:	2025	Market Size in 2026:	USD 636.4 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	3.40%	2033 Value Projection:	USD 804.3 Mn

Alpha-1 deficiency-related emphysema is called as genetic Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic illness, and some of its symptoms include wheezing, mucus production, and breathing difficulties. Chronic bronchitis, emphysema, and refractory asthma are all symptoms of COPD, a degenerative lung condition. Chronic obstructive pulmonary disease (COPD) is mostly brought on by smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (a rare form of COPD), and other factors.

Each year, millions of people are affected by chronic obstructive pulmonary disease, or COPD for short. Emphysema and chronic bronchitis are two conditions that are collectively referred to as COPD. The lungs' alveoli, which are air sacs, suffer damage in emphysema. Breathlessness while exercising is the first sign of emphysema. Later, breathing difficulties can also happen while at rest. The four stages of chronic obstructive pulmonary disease (COPD) range from mild to very severe. Some symptoms may include an ongoing cough, shortness of breath, and wheezing.

Market Dynamics

Increasing adoption of organic strategies by key players in market such as product launch and approval is expected to drive market growth over the forecast period. For instance, in September 2020, GSK, Plc.,a pharmaceutical company and Innoviva Inc., a healthcare focused asset management company, announced that the U.S. Food and Drug Administration (FDA) approved a new indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol 'FF/UMEC/VI') for the treatment of asthma in patients 18 years and older, expanding the current approval for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for the relief of acute bronchospasm. Moreover, several prospective drugs, primarily for COPD, are in the pipeline for respiratory illnesses, which is anticipated to boost growth of the global genetic chornic obstructive pulmonary disease (COPD) market.

Key features of the study:

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
it profiles key players in the global genetic chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study GSK Plc., AstraZeneca Plc., Merck (Sigma-Aldrich), Dey Pharma, Grifols, S.A., Teva Pharmaceutical Industries Ltd, Baxter, Boehringer Ingelheim International GmbH, Kamada Ltd, Takeda Pharmaceutical Company Limited, LFB SA, Abeona Therapeutics, Alnylam Pharmaceuticals, Inc., Vertex Pharmaceuticals Incorporated, Kedrion S.p.A., and Arrowhead Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global genetic chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global genetic chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation:

Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class (Revenue, USD Mn, 2021 - 2033)
Bronchodilators
Phosphodiesterase Type 4 Inhibitors
Steroids
Antibiotics
Others
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration (Revenue, USD Mn, 2021 - 2033)
Oral
Nasal
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel (Revenue, USD Mn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region (Revenue, USD Mn, 2021 - 2033)
North America
- By Country
  - U.S.
  - Canada
Latin America
- By Country
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- By Country
  - Germany
  - U.K.
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- By Country
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- By Country
  - GCC
  - Israel
  - Rest of Middle East
Africa
- By Region/Country
  - South Africa
  - Central Africa
  - North Africa
Company Profiles
GSK Plc*
- Company Highlights
- Products Portfolio
- Key Highlights
- Financial Performance
- Strategies
AstraZeneca Plc
Merck (Sigma-Aldrich)
Dey Pharma
Grifols, S.A.
Teva Pharmaceutical Industries Ltd
Baxter
Boehringer Ingelheim International GmbH
Kamada Ltd
Takeda Pharmaceutical Company Limited.
LFB SA
Abeona Therapeutics
Alnylam Pharmaceuticals, Inc.
Vertex Pharmaceuticals Incorporated
Kedrion S.p.A.
Arrowhead Pharmaceuticals, Inc

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snapshot, By Drug Class
- Market Snapshot, By Route Of Administration
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Regulatory Scenario
Key Highlights
Research and Development Collaboration, Mergers, and Acquisitions
PEST Analysis
Pipeline Analysis
Epidemiology

4. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Drug Class, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Bronchodilators
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Phosphodiesterase Type 4 Inhibitors
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Steroids
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Antibiotics
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Others
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

5. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Route Of Administration, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Oral
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Nasal
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

6. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Distribution Channel, 2021 - 2033, (US$ Million)

Overview
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Retail Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)
Online Pharmacies
- Overview
- Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (US$ Million)

7. Global Genetic Chronic Obstructive Pulmonary Disease (COPD) Market, By Region, 2021 - 2033, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Regions, 2022-2033
- Regional Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Million)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Million)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 - 2033, (US$ Million)
  - North Africa
  - Central Africa
  - South Africa

8. Competitive Landscape

Heat Map Analysis
Company Profiles
- GSK Plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- AstraZeneca Plc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Merck (Sigma-Aldrich)
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Dey Pharma
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Grifols, S.A.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Teva Pharmaceutical Industries Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Baxter
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Boehringer Ingelheim International GmbH
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Kamada Ltd
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Takeda Pharmaceutical Company Limited
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- LFB SA
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Abeona Therapeutics
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Alnylam Pharmaceuticals, Inc.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Vertex Pharmaceuticals Incorporated
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Kedrion S.p.A.
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies
- Arrowhead Pharmaceuticals, Inc
  - Company Highlights
  - Product Portfolio
  - Key Highlights
  - Financial Performance
  - Market Strategies

9. Section

References
Research Methodology
About Us and Sales Contact

유전성 만성 폐쇄성 폐질환(COPD) 시장 : 약제 클래스별, 투여 경로별, 유통 채널별 및 지역별